Dharmacon, Inc.
Records under this name other than the patents Dharmacon, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 13 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,980,855 | Minor Groove Binder (MGB)-Oligonucleotide Mirna Antagonists Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,334,495 | Minor groove binder (MGB)-oligonucleotide miRNA antagonists Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,691,997 | Functional and Hyperfunctional Sirna Formerly held Term ended Term ended Feb 28, 2026 · Medium confidence | Term ended | Term ended Feb 28, 2026 | Medium confidence |
| US 8,546,349 | Sirna Targeting Vegfa and Methods for Treatment in Vivo Formerly held Lapsed on the fee record Ended Oct 1, 2025 · High confidence | Lapsed on the fee record | Ended Oct 1, 2025 | High confidence |
| US 8,304,528 | Sirna Targeting FRUCTOSE-1, 6-Bisphosphatase 1 (FBP1) Formerly held Term ended Term ended Sep 9, 2024 · High confidence | Term ended | Term ended Sep 9, 2024 | High confidence |
| US 8,247,169 | Sirna Targeting Diacylglycerol O-Acyltransferase Homolog 2 (DGAT2) Formerly held Term ended Term ended Aug 3, 2024 · High confidence | Term ended | Term ended Aug 3, 2024 | High confidence |
| US 7,745,610 | Sirna Targeting Cyclin Dependent Kinase 11 (CDK11) Formerly held Term ended Term ended Jul 25, 2024 · High confidence | Term ended | Term ended Jul 25, 2024 | High confidence |
| US 8,236,942 | Sirna Targeting Glucagon Receptor (GCGR) Formerly held Term ended Term ended Jun 21, 2024 · High confidence | Term ended | Term ended Jun 21, 2024 | High confidence |
| US 8,198,427 | Sirna Targeting Catenin, BETA-1 (CTNNB1) Formerly held Lapsed on the fee record Ended Jun 12, 2024 · High confidence | Lapsed on the fee record | Ended Jun 12, 2024 | High confidence |
| US 8,030,474 | Sirna Targeting Cyclin-Dependent Kinase 4 (CDK4) Formerly held Term ended Term ended May 21, 2024 · High confidence | Term ended | Term ended May 21, 2024 | High confidence |